AGMB (AgomAb Therapeutics NV) Preferred Stock: $0.00 Mil (As of Dec. 2025)


AGMB AgomAb Therapeutics NV AGMB
14 GF Score
Price $13.08
! 1 Warning Sign
View Full Analysis

What is AgomAb Therapeutics NV Preferred Stock?

AgomAb Therapeutics NV AGMB +0.85% 14 Preferred Stock is $0.00 Mil as of Dec. 2025. GuruFocus rates AGMB with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

Preferred stock is a special equity security that has properties of both equity and debt. AgomAb Therapeutics NV's preferred stock for the quarter that ended in Dec. 2025 was $0.00 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. AgomAb Therapeutics NV's Enterprise Value for the quarter that ended in Dec. 2025 was $-135.26 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. AgomAb Therapeutics NV's Book Value per Share for the quarter that ended in Dec. 2025 was $3.15.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). AgomAb Therapeutics NV's Earnings per Share (Diluted) for the three months ended in Dec. 2025 was $-0.42.


AgomAb Therapeutics NV  (NAS:AGMB) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

AgomAb Therapeutics NV's Enterprise Value for the quarter that ended in Dec. 2025 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

AgomAb Therapeutics NV's Book Value per Share for the quarter that ended in Dec. 2025 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

AgomAb Therapeutics NV's Earnings per Share (Diluted) (EPS) for the three months ended in Dec. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AgomAb Therapeutics NV Preferred Stock Related Terms


AgomAb Therapeutics NV Preferred Stock Historical Data

* Premium members only.

The historical data trend for AgomAb Therapeutics NV's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AgomAb Therapeutics NV Preferred Stock Chart

AgomAb Therapeutics NV Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Preferred Stock
0.00 0.00 0.00 0.00 0.00

AgomAb Therapeutics NV Quarterly Data
Dec21 Dec22 Dec23 Dec24 Sep25 Dec25
Preferred Stock Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
AGMB
14GF Score
AgomAb Therapeutics NV AGMB
Preferred Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AgomAb Therapeutics NV Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.

Frequently Asked Questions Learn more about Preferred Stock →
What does a Preferred Stock of $0.00 Mil mean?
AgomAb Therapeutics NV (AGMB) has a Preferred Stock of $0.00 Mil as of Dec. 2025. Preferred Stock represents the par value of a company's preferred shares. View historical data on AgomAb Therapeutics NV and its competitors.
Is AgomAb Therapeutics NV's Preferred Stock too high?
AgomAb Therapeutics NV's current Preferred Stock is $0.00 Mil. Overall, AgomAb Therapeutics NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AgomAb Therapeutics NV's Preferred Stock compare to DNA and ACRS?
AgomAb Therapeutics NV's Preferred Stock of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Preferred Stock for a Biotechnology company?
A good Preferred Stock depends on the Biotechnology industry context. However, Preferred Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Preferred Stock mean?
A high Preferred Stock can signal that a stock is expensive relative to its fundamentals. Preferred Stock represents the par value of a company's preferred shares. View historical data on AgomAb Therapeutics NV and its competitors. AgomAb Therapeutics NV's current Preferred Stock is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AgomAb Therapeutics NV stock overvalued right now?
AgomAb Therapeutics NV (AGMB) has a current Preferred Stock of $0.00 Mil. The current Preferred Stock is $0.00 Mil. AgomAb Therapeutics NV's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Preferred Stock calculated?
Preferred Stock is calculated from a company's financial statements. For AgomAb Therapeutics NV (AGMB), the current Preferred Stock is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AgomAb Therapeutics NV Business Description

Address 1/6 Posthoflei, Antwerp, BEL, 2600
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score

Get the complete analysis for AGMB

Preferred Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.08
Price